# POLE

## Overview
The POLE gene encodes the catalytic subunit of DNA polymerase epsilon, a crucial enzyme involved in DNA replication and repair. This enzyme is categorized as a polymerase and plays a significant role in ensuring the high fidelity of DNA synthesis, particularly during leading-strand replication. The protein encoded by POLE contains a proofreading exonuclease domain, which is essential for correcting misincorporated nucleotides, thereby maintaining genomic stability and preventing mutations. Mutations in the POLE gene, especially those affecting the exonuclease domain, can lead to increased mutation rates and are associated with various cancers, including colorectal and endometrial cancers. The enzyme's interactions with other proteins and its involvement in cell cycle control and DNA damage response underscore its importance in cellular processes and its potential as a molecular marker in cancer prognosis and treatment (Church2013DNA; Ma2022POLEPOLD1; Henninger2014DNA).

## Structure
The POLE protein, encoded by the POLE gene, is the catalytic subunit of DNA polymerase epsilon, which plays a crucial role in DNA replication and repair. The protein's structure includes a proofreading exonuclease domain at the amino terminus, essential for high-fidelity DNA synthesis by removing misincorporated nucleotides. This domain is organized around a central β-sheet containing the active site, forming a ring-shaped structure with the polymerase domain that accommodates the template-primer duplex DNA (Shevelev2002The).

The exonuclease activity of POLE is facilitated by a two-metal-ion-catalyzed phosphoryl transfer mechanism, similar to the one used in polymerization, allowing the polymerase to switch between 'polymerizing' and 'editing' modes (Shevelev2002The). Mutations in the exonuclease domain, such as p.Pro286Arg and p.Val411Leu, can significantly alter the DNA-binding pocket and affect the protein's proofreading ability, leading to increased mutation rates and cancer predisposition (Church2013DNA).

The POLE protein may undergo post-translational modifications, such as phosphorylation, which can influence its function. Splice variants of POLE can result in different isoforms, potentially affecting its role in DNA replication and repair. However, specific details on these aspects are not provided in the context.

## Function
The POLE gene encodes the catalytic subunit of DNA polymerase epsilon (Pol ε), which is essential for DNA replication and repair in human cells. Pol ε plays a critical role in leading-strand synthesis during DNA replication, ensuring high fidelity and genomic stability through its polymerase and exonuclease activities (Park2019POLE; Henninger2014DNA). The exonuclease activity of Pol ε is particularly important for proofreading, as it removes misincorporated nucleotides, thereby preventing mutations and maintaining genome integrity (Robinson2021Increased; Henninger2014DNA).

Pol ε is active in the nucleus, where it participates in cell cycle control and DNA damage response, contributing to proper cell division and organismal development (Henninger2014DNA). It is also involved in epigenetic maintenance, particularly in the propagation of epigenetic marks during DNA replication, and is associated with chromatin remodeling complexes (Henninger2014DNA). The enzyme's fidelity is attributed to its intrinsic base selectivity and proofreading capabilities, which are crucial for replicating bulk genomic DNA and preventing the accumulation of mutations that could lead to genomic instability and cancer (Park2019POLE; Henninger2014DNA).

## Clinical Significance
Mutations in the POLE gene, which encodes the catalytic subunit of DNA polymerase epsilon, are clinically significant in several cancers due to their impact on DNA replication fidelity. In colorectal cancer (CRC), POLE mutations are associated with a high tumor mutation burden (TMB) and distinct clinical patterns, including early-onset disease and familial cancer syndromes (Jiang2022Distinct; Ma2022POLEPOLD1). These mutations often occur in the exonuclease domain, leading to a loss of proofreading function and increased mutation rates, which can result in hypermutated tumors (Jiang2022Distinct; Ma2022POLEPOLD1).

In endometrial cancer (EC), POLE mutations are present in about 10% of patients and are linked to a high TMB and favorable prognosis, often occurring in younger patients with lower recurrence rates (Ma2022POLEPOLD1). In non-small cell lung cancer (NSCLC), POLE mutations are found in 2.8% of patients and are associated with high TMB and improved overall survival in certain subtypes (Ma2022POLEPOLD1).

Germline mutations in POLE, such as p.Leu424Val, are implicated in familial colorectal cancer and polyposis, with a phenotype that includes multiple adenomas and early-onset CRC (Spier2015Frequency; Valle2014New). These mutations are considered important molecular markers for prognosis and treatment guidance across various cancers (Ma2022POLEPOLD1).

## Interactions
DNA polymerase epsilon (Pol ε), encoded by the POLE gene, is a key component of the DNA replication machinery and interacts with several proteins and nucleic acids. Pol ε is a holoenzyme composed of four subunits, with the catalytic subunit encoded by POLE. It interacts with other subunits such as POLE2, which is crucial for its stability and recruitment to the replication fork (Vipat2022The). The interaction between POLE1 and POLE2 is essential for DNA synthesis, as the C-terminal zinc-finger region of POLE1 binds to POLE2, stabilizing it during replication initiation (Vipat2022The).

Pol ε also plays a significant role in the assembly and activation of the CMG replicative helicase, which is essential for chromosomal replication. It forms a complex with proteins such as GINS, Dpb11, and Sld2, which are part of the replicative helicase complex, contributing to the stability and progression of the replication fork (Henninger2014DNA). In addition, Pol ε interacts with checkpoint mediators like claspin/Mrc1, which help retain it at the leading strand during replication stress (Henninger2014DNA). These interactions highlight the multifaceted role of Pol ε in maintaining genome stability through its involvement in DNA replication and repair processes.


## References


[1. (Shevelev2002The) Igor V. Shevelev and Ulrich Hübscher. The 3′–5′ exonucleases. Nature Reviews Molecular Cell Biology, 3(5):364–376, May 2002. URL: http://dx.doi.org/10.1038/nrm804, doi:10.1038/nrm804. This article has 217 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrm804)

[2. (Church2013DNA) David N. Church, Sarah E.W. Briggs, Claire Palles, Enric Domingo, Stephen J. Kearsey, Jonathon M. Grimes, Maggie Gorman, Lynn Martin, Kimberley M. Howarth, Shirley V. Hodgson, Kulvinder Kaur, Jenny Taylor, and Ian P.M. Tomlinson. Dna polymerase ɛ and δ exonuclease domain mutations in endometrial cancer. Human Molecular Genetics, 22(14):2820–2828, March 2013. URL: http://dx.doi.org/10.1093/hmg/ddt131, doi:10.1093/hmg/ddt131. This article has 305 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddt131)

[3. (Vipat2022The) Sameera Vipat, Dipika Gupta, Sagun Jonchhe, Hele Anderspuk, Eli Rothenberg, and Tatiana N. Moiseeva. The non-catalytic role of dna polymerase epsilon in replication initiation in human cells. Nature Communications, November 2022. URL: http://dx.doi.org/10.1038/s41467-022-34911-4, doi:10.1038/s41467-022-34911-4. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-34911-4)

[4. (Spier2015Frequency) Isabel Spier, Stefanie Holzapfel, Janine Altmüller, Bixiao Zhao, Sukanya Horpaopan, Stefanie Vogt, Sophia Chen, Monika Morak, Susanne Raeder, Katrin Kayser, Dietlinde Stienen, Ronja Adam, Peter Nürnberg, Guido Plotz, Elke Holinski‐Feder, Richard P. Lifton, Holger Thiele, Per Hoffmann, Verena Steinke, and Stefan Aretz. Frequency and phenotypic spectrum of germline mutations in <scp>pole</scp> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. International Journal of Cancer, 137(2):320–331, January 2015. URL: http://dx.doi.org/10.1002/ijc.29396, doi:10.1002/ijc.29396. This article has 111 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.29396)

[5. (Robinson2021Increased) Philip S. Robinson, Tim H. H. Coorens, Claire Palles, Emily Mitchell, Federico Abascal, Sigurgeir Olafsson, Bernard C. H. Lee, Andrew R. J. Lawson, Henry Lee-Six, Luiza Moore, Mathijs A. Sanders, James Hewinson, Lynn Martin, Claudia M. A. Pinna, Sara Galavotti, Raheleh Rahbari, Peter J. Campbell, Iñigo Martincorena, Ian Tomlinson, and Michael R. Stratton. Increased somatic mutation burdens in normal human cells due to defective dna polymerases. Nature Genetics, 53(10):1434–1442, September 2021. URL: http://dx.doi.org/10.1038/s41588-021-00930-y, doi:10.1038/s41588-021-00930-y. This article has 98 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41588-021-00930-y)

[6. (Ma2022POLEPOLD1) Xiaoting Ma, Lin Dong, Xiu Liu, Kai Ou, and Lin Yang. Pole/pold1 mutation and tumor immunotherapy. Journal of Experimental &amp; Clinical Cancer Research, July 2022. URL: http://dx.doi.org/10.1186/s13046-022-02422-1, doi:10.1186/s13046-022-02422-1. This article has 55 citations.](https://doi.org/10.1186/s13046-022-02422-1)

[7. (Valle2014New) Laura Valle, Eva Hernández-Illán, Fernando Bellido, Gemma Aiza, Adela Castillejo, María-Isabel Castillejo, Matilde Navarro, Nuria Seguí, Gardenia Vargas, Carla Guarinos, Miriam Juarez, Xavier Sanjuán, Silvia Iglesias, Cristina Alenda, Cecilia Egoavil, Ángel Segura, María-José Juan, María Rodriguez-Soler, Joan Brunet, Sara González, Rodrigo Jover, Conxi Lázaro, Gabriel Capellá, Marta Pineda, José Luís Soto, and Ignacio Blanco. New insights into pole and pold1 germline mutations in familial colorectal cancer and polyposis. Human Molecular Genetics, 23(13):3506–3512, February 2014. URL: http://dx.doi.org/10.1093/hmg/ddu058, doi:10.1093/hmg/ddu058. This article has 125 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddu058)

[8. (Park2019POLE) Vivian S. Park and Zachary F. Pursell. Pole proofreading defects: contributions to mutagenesis and cancer. DNA Repair, 76:50–59, April 2019. URL: http://dx.doi.org/10.1016/j.dnarep.2019.02.007, doi:10.1016/j.dnarep.2019.02.007. This article has 49 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.dnarep.2019.02.007)

[9. (Jiang2022Distinct) Miao Jiang, Yongliang Jia, Jinming Han, Jianxiang Shi, Chang Su, Rui Zhang, Menglu Xing, Shuiling Jin, and Hong Zong. Distinct clinical pattern of colorectal cancer patients with pole mutations: a retrospective study on real-world data. Frontiers in Genetics, November 2022. URL: http://dx.doi.org/10.3389/fgene.2022.963964, doi:10.3389/fgene.2022.963964. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.963964)

[10. (Henninger2014DNA) Erin E. Henninger and Zachary F. Pursell. Dna polymerase ε and its roles in genome stability. IUBMB Life, 66(5):339–351, May 2014. URL: http://dx.doi.org/10.1002/iub.1276, doi:10.1002/iub.1276. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/iub.1276)